Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Helsinn Investment Fund

Investor type Micro VC


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 23
Average round size
The average size of a deal this fund participated in
Portfolio companies 16
Rounds per year 3.83
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 2
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Biopharma
  • Health Care
  • Therapeutics
  • Medical

The fund has exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Health Care, Biometrics. Among the various public portfolio startups of the fund, we may underline OncoResponse, On Target Laboratories, Personal Genome Diagnostics (PGD) Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Helsinn Investment Fund performs on 15 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2019. The top activity for fund was in 2018. The fund is constantly included in 2-6 investment rounds annually.

The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Helsinn Investment Fund, startups are often financed by VI Partners AG, High-Tech Gru00fcnderfonds, Boehringer Ingelheim Venture Fund. The meaningful sponsors for the fund in investment in the same round are Windham Venture Partners, VI Partners AG, Schroder Adveq. In the next rounds fund is usually obtained by VI Partners AG, Schroder Adveq, RiverVest.

We also calculated 2 valuable employees in our database.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Acorn Pacific Ventures California, Santa Clara, United States
CoxHealth -
DCM Data Systems Gurgaon, Haryana, India
JIC Venture Growth Investments Chiyoda, Japan
Lukka New York, New York, United States
MeetMe New Hope, Pennsylvania, United States
Pingguo Shu Ziben Beijing, Beijing, China
Sunshine 100 China Beijing, Beijing, China
Ucommune Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Domain Therapeutics

Health Care
$46M10 May 2022 France, Grand Est, France

Kither Biotech

Life Science
$21M16 Mar 2022 Turin, Piemont, Italy

IGEM Therapeutics

02 Mar 2022 London, England, United Kingdom


$1M26 Oct 2021 -

GreenBone Ortho

$11M13 Apr 2021 Italy, Emilia-Romagna, Italy


Health Care
$40M31 Mar 2021 Seattle, Washington, United States

On Target Laboratories

Life Science
$21M24 Mar 2021 Illinois, United States


Translation Service
$20M09 Mar 2021 Cambridge, England, United Kingdom


Health Care
Medical Device
$6M14 Jul 2020 Geneva, Geneva, Switzerland
On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection

– On Target Laboratories secured $21m in an expanded Series B funding round.
– The funds will support the continued development and commercialization of the company’s novel compound, pafolacianine sodium injection.
– The funding was wholly backed by existing investors Johnson & Johnson Innovation – JJDC, Inc., H.I.G. Capital, Elevate Ventures, The Hurvis Group, and 3B Future Health Fund (formally Helsinn Investment Fund).
– The funds will drive the commercialization of the company’s first indication in ovarian cancer.
– The funding will also be used to complete the ELUCIDATE Trial, a Phase 3 clinical trial evaluating the use of pafolacianine sodium injection to intraoperatively identify lung cancer in real-time.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Helsinn Investment Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: